06 Apr 2026

CRC Research Update — April 06, 2026

Creator: The CRC Digest
Published: 2026-04-06T11:58:22Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Circulating tumor DNA shows promise for guiding adjuvant therapy decisions after CRC surgery
A scoping review synthesizes evidence on ctDNA-based minimal residual disease testing in resected colorectal cancer, comparing tumor-informed versus plasma-only approaches to detect recurrence risk and personalize post-surgery treatment. (Journal of Gastrointestinal Surgery)
Rare case shows dramatically different immunotherapy responses in same patient with two colon tumors
Synchronous transverse colon cancers with discordant mismatch repair status demonstrated strikingly divergent responses to neoadjuvant immune checkpoint inhibitors — the dMMR tumor responded while the pMMR tumor did not. (Japanese Journal of Clinical Oncology)
Blocking bile acid pathway may enhance immunotherapy effectiveness in colorectal cancer
Research identifies glycocholic acid-regulated signaling as a potential target to improve immune checkpoint therapy responses in CRC patients. (Nature Communications)
AI model using CT scans predicts microsatellite instability before surgery in multicenter study
A deep learning radiomics model analyzing 873 CRC patients across three medical centers improved preoperative MSI prediction using enhanced CT images and body composition data. (European Journal of Radiology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

UAB doctor urges earlier screening as colorectal cancer rises among younger adults
Physicians emphasize the importance of earlier screening as CRC incidence continues to increase in patients under 50. (WBRC)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Fecal hemoglobin testing linked to improved colorectal cancer survival
Research suggests that fecal hemoglobin screening may contribute to better survival outcomes in colorectal cancer patients. (Bioengineer.org)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

ctDNA testing offers noninvasive approach to detect minimal residual disease after surgery
Scoping review examines how circulating tumor DNA can guide adjuvant therapy decisions and surveillance strategies in resected CRC. (Journal of Gastrointestinal Surgery)
MSI-H tumor responds to immunotherapy while MSI-stable tumor does not in same patient
Exceptional case of synchronous colon cancers with different MMR status provides direct in vivo evidence of ICI responsiveness differences. (Japanese Journal of Clinical Oncology)

These advances in biomarker testing and personalized treatment continue to expand options for CRC patients at every stage.

CRC Research Update

Subscribe to The CRC Digest